The role of gut mycobiome in health and diseases

Lin Zhang*, Hui Zhan*, Wenye Xu, Shuai Yan and Siew C. Ng

Abstract: The gut microbiome comprised of microbes from multiple kingdoms, including bacteria, fungi, and viruses. Emerging evidence suggests that the intestinal fungi (the gut “mycobiome”) play an important role in host immunity and inflammation. Advances in next generation sequencing methods to study the fungi in fecal samples and mucosa tissues have expanded our understanding of gut fungi in intestinal homeostasis and systemic immunity in health and their contribution to different human diseases. In this review, the current status of gut mycobiome in health, early life, and different diseases including inflammatory bowel disease, colorectal cancer, and metabolic diseases were summarized.

Keywords: Gut fungi, Mycobiome, Early life, Health, Disease

Received: 14 March 2021; revised manuscript accepted: 31 August 2021.

Introduction
Most studies of the human gut microbiome have focused on the bacterial component of the microbiome, but the fungal microbiome (i.e. the mycobiome) has recently gained recognition as a fundamental part of the human microbiome. Fungi inhabit the mucosal surface to maintain intestinal homeostasis and systemic immunity. Until recently, there has been a lack of research focusing on the interactions of the fungal kingdom of microorganisms with other constituents of the gut microbiome and their contribution to health and diseases. To date, less than 3% of the microbiome literature accounts for the presence of fungi in microbial communities. Recent advances in sequencing technology have provided comprehensive tools to profile the fungal component of the gut microbiome and emerging data suggest that the gut mycobiome may act as a reservoir for potentially opportunistic pathogens in inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), gastrointestinal cancer, and other diseases. Here, we discuss the importance of developing standardized methodology to define the gut mycobiome in early life, health, and diseases. We also highlight future directions of studies to delineate the role of gut mycobiome and the potential of therapeutic intervention targeting the gut mycobiome.

Methods to characterize the gut mycobiome
Characterization of the gut mycobiome has been complicated by the lack of comprehensive, well-curated, and high-resolution taxonomic annotation within fungal databases. Development of standardized methods for mycobiome analyses is critical to minimize variations across studies. A comprehensive literature search using broad searching criteria was conducted in the PubMed and Google Scholar databases. In short, 103 relevant literatures related to gut mycobiome are carefully selected based on the key words including “gut mycobiome”, “fungi”, “fungus”, “eukaryotes”, “fungal community”, “yeast”, and “sequencing”. The fungal study workflow contains extraction, library construction, and sequencing, and bioinformatic analysis was shown in Figure 1(a). There were 33 different commercial extraction kits used for fungi studies with 13 customized protocols. QIAamp DNA Mini Kit (Qiagen) was the most commonly used kit in 16 papers. Fast DNA Spin Kit (MP Biomedicals) was a common extraction kit for fungi. About 90% of users selected next generation sequencing (NGS) platform for higher throughput and faster turnaround time. Among all the
Figure 1. The fungal study workflow contains extraction, libraries construction, sequencing, and bioinformatic analysis. (a) Initially DNA/RNA will be isolated from fungal samples. Then DNA or RNA extraction was performed following the protocol of amplicon, metagenomics, and metatranscriptomics according to strategy. Depending on strategy of research, different sequencer is selected from first-generation sequencing to third-generation sequencing. Generally, next generation sequencing (NGS) platform is chosen by higher output like Illumina sequencing by synthesis (SBS) sequencing technology, while third generation sequencing has also become competitive for sequence full-length small genomes without assembly like Pacbio Single-molecule real-time (SMRT) sequencing. Analyze sequencing data using amplicon, metagenomics, and metatranscriptomics bioinformatics pipeline to analysis 16S rRNA/rDNA, DNA and RNA, respectively.  

(b) Among the studies involving sequencing methods, there are 10 sequencing platforms are used, in which NGS platform is used frequently and Illumina MiSeq platform is used the most in NGS method. 

(c) The fungal sequencing strategies are the study of ITS region, analysis of 16S rRNA/rDNA and 18S rRNA/rDNA gene. (d) ITS sequences and commonly and locatable primers used in fungal target region.
sequencing platforms, Illumina MiSeq platform is the most widely utilized sequencer for 16S amplicon (Figure 1(b)). Widely used platform of NGS is Illumina which has high throughput, high quality, and high speed for large number of samples. Compared with Nanopore which belongs to one of the third-generation sequencing (TGS) technique, Illumina sequencers involve the following features: (1) it has implemented hundreds of metabarcoding of complex samples per run through dual-index method compared with less than 24 sequences in a Nanopore single run.76 (2) It has high-quality rate with 99.99% accuracy higher than approximately 90% of Nanopore.77 (3) For each sequencing run of massive fungal specimen, the MiSeq generates 24Gbp with PE300 and the NovaSeq 6000 generates 2190Gbp with PE150, respectively, but 10Gbp was generated by MinION in general research lab.78 With the continuous development of sequencing technology, new technologies have been used in research to identify fungi, especially Nanopore,79 and TGS sequencers have two significant advantages compared with Illumina. Initially, as an advantage of long reads sequencing in Nanopore, 0–200 kbp DNA could be covered, while 400–600 bp reads are sequenced in illumina sequencing. Long fragment could be reconstructed and identified as species precisely, decreasing the number of mislabeled species identified in illumine.80 Secondarily, researches use Nanopore to detect fungi for the advantage of amplicon-based and PCR-free metagenomics technology.77

For sequencing strategy, as indicated in Figure 1(c), 50% of articles sequenced the internal transcribed spacer (ITS) region, including ITS1 and ITS2, while 32% articles focused on 16s rRNA/rDNA gene and 10% papers on 18s rRNA/rDNA regions. Only 3% of the papers have performed metagenomics and 4% with metatranscriptomic fungal analysis. The fungal ribosomal region contains the internal transcribed spacers (ITS1 and ITS2) and the 5.8s, 18s, and 28s rRNA (Figure 1(d)). Currently, ITS1 and ITS211–16,51,58,65,66,73,75,81 are two major optional primers for human gut mycobiome study and the primer ITS2 is longer than primer ITS1 which has lower species resolution but fewer amplification and sequencing errors.82 Besides, the primer ITS1 is biased toward the amplification of Basidiomycetes and the primer ITS2 for the Ascomycetes.83 There were also reported ITS target regions outperformed compared with other subunit rRNA region in the human microbiome.28 Because ITS regions show not only fewer number of ribosomal gene copies but also less relative abundance of variants and breakpoints in various regions per unit in human rDNA.84 A preview results nonetheless support that the result of 18s rDNA PCR, which compares with one of ITS PCR, shows significant diagnostic and accurate identification of fungal pathogens in clinical sample from fresh biopsies and punctate and deep wound secretions.85 Compared with target sequence, metagenomics reads might be decreased biases from primer choices and increased community taxonomic characterization providing information of gene composition and the function.86

Overall, although significant advancements have been made on bioinformatics methodologies for gut mycobiome analyses, further development of pipelines and databases is required to define and characterize fungal communities more accurately.

The gastrointestinal tract mycobiome
Fecal samples are the most commonly used specimens to represent the human gut mycobiome. According to Human Microbiome Project, Saccharomyces, Malassezia, Candida, Cyberlindnera, Penicillium, Cladosporium, Aspergillus, Debaryomyces, Pichia, Clavispora, and Galactomyces are the most prevalent fungal genera in the human gut based on ITS2 and 18S rRNA sequencing.87 Cultivable gut mycobiota including Candida albicans, Candida glabrata, Candida deformans, Aspergillus glaucus, Cryptococcus satos, Cryptococcus neoformans, Lichtheimia ramosa, Mucor circinelloides, Pseudostrongophora richardsiae, Rhodotorula mucilaginosa, Trichosporon asahii and Yarrowia lipolytica are frequently isolated from human feces.88,89 By pyrosequencing, Hoffmann et al.90 have found 12 fungal genera in fecal samples and Saccharomyces (present in 89% of the samples) was the most dominant. In another study of 45 healthy individuals, a total of 72 distinct operational taxonomic units (OTU) of gut fungi were found using ITS sequencing. Candida tropicalis, Geotrichum gigas, C. sake, and Phichia jadinii were the most commonly detected fungal microbiota from the fecal samples.91 Moreover, edible mushrooms (Agaricus bisporus) and plant pathogen (Epicoccum nigrum and Alternaria spp.) were also identified in the gastrointestinal tract of vegetarian individuals.43 Fecal-associated mycobiome are less
Mucosa is also colonized by fungi. Compared with luminal-associated gut mycobiota, a more stable fungal community was found in the intestinal mucosa.

Factors affecting the gut mycobiome

Despite emerging research on the gut mycobiome, a consensus healthy mycobiome has yet to be established. Several factors have been shown to be associated with alterations in mycobiota community composition including host genetics, gender, age, comorbidities, drugs, lifestyle factors including hygiene, socioeconomic status, diet, occupation, and the immune system. Interestingly, unlike the bacteriome, the mycobiome was shown a higher diversity in highly acidic stomach environment in piglet. This suggested that the imbalance of gut mycobiota may be related to stomach disease. Indeed, recent study reveals a perturbation of fungal compositional and ecological changes in gastric cancer development and C. albi-
cans was characterized as a biomarker for gastric cancer. Given that early life factors are known to influence host microbiome status, data on early life gut mycobiome and factors influencing their development were reviewed.

Early life gut mycobiota

Early life fungal colonization has an impact on health outcomes of infants by training their immune system. Gut mycobiome in early life and factors that influence their development are shown in Figure 2. Infant fecal mycobiome was characterized by a low relative abundance of fungi composition and richness. Mother and infant fecal mycobiome were profiled in 15 mother–infant pairs in the first year of life by 18s rRNA gene amplicon sequencing. Phyla Basidiomycota and Ascomycota, with the genus Saccharomyces and the class Exobasidiomycetes, were the most represented fungal component found in meconium. In another study, fecal samples from 298 mother–offspring pairs were analyzed by ITS1 amplicon sequencing. S. cerevisiae was the most abundant species in the gut of infants from 1 year of age onwards. Besides, Debaryomyces hansenii prevailed up to 3 months in the infant’s feces. The 10-day, 1-year, and 2-year fecal samples from infants were richer in R. mucilaginosa, whereas the 3-month samples showed a high colonizer of C. parapsilosis. To further investigate early fungal community establishment, Ward et al. assessed the skin, oral, and anal mycobiomes of 16 infants over the first month of life and the anal and vaginal mycobiomes of 17 mothers using ITS2 amplicon sequencing. Infant mycobiomes varied by three body sites; skin mycobiome were dominated by C. tropicalis, C. parapsilosis, S. cerevisiae, C. albicans, and C. orthopsilosis; oral mycobiome was enriched with C. parapsilosis, C. tropicalis, S. cerevisiae, C. orthopsilosis, C. albicans, and Cladosporium velox; and anal mycobiome were colonized with C. parapsilosis, C. tropicalis, C. albicans, S. cerevisiae, C. orthopsilosis, and Cryptococcus pseu-
dolongus, respectively. However, the infant’s mycobiome did not show a trajectory toward maturity within first 30 days of life, and this could be in part explained by the use of a relatively consistent food source of either breast milk or infant formula. Moreover, Kasper has demonstrated that mycobiota could be transferred from mothers to their offspring. In the study, five infants shared D. hansenii and S. cerevisiae observed in their mothers. Notably, the mother-to-child bacterial transmission patterns have been well profiled at strain level, whereas limited studies on mother-to-child vertical fungal transmission were reported. Overall, these studies all demonstrated that fungi could colonize in the neonatal gut at very early stage; nevertheless, how the mycobiome is shaped and how the succession occurs in the gut of neonates remained to be elucidated in the future.
Figure 2. The gut mycobiome through life and the influencing factors in early life. Infants receive mycobiota colonization in the gut at birth, and fungal community increased with age in infancy but decreased when they grow up to young adults. 10 days after birth, *Rhodotorula mucilaginosa* and *Debaryomyces hansenii* predominated in the gut of infants, while *Candida parapsilosis, C. tropicalis, C. albicans, Saccharomyces cerevisiae, C. orthopsilosis*, and *Cryptococcus pseudolongus* enriched in the anus of infants in the first month. In the adult stage, *C. albicans, S. cerevisiae, C. tropicalis, C. glabrata, C. deforans*, and *Aspergillus glaucus* occupy the gut. In later years, *Penicillium, Candida, Aspergillus*, and *Saccharomyces* were dominant in the gut of elders. The major factors contributing to neonatal gut fungal communities were mode of feeding and mode of delivery. Compared with neonates by cesarean section, a higher level of *Candida* and *Pleosporales*, decreased level of *Malassezia* were shown in the gut of infants born via vaginal delivery. Moreover, infants could directly acquire mycobiota from breast milk feeding by their mothers, which contains abundant *R. mucilaginosa* and *C. parapsilosis*.

Factors affecting mycobiome in early life

Fungi are ubiquitous in the environment and the infant mycobiome may originate from the mother during birth, from the mother’s breast milk, parental skin, or anywhere else in the hospital or home environment with which the offspring come in contact with.\(^{100}\)

*Mode of delivery.* In newborn babies, initial fungal colonization is largely dependent on delivery mode (Figure 2). Infants born vaginally obtained fungi that colonize the vagina, whereas infants born via Caesarian section acquire fungal species that are related to the skin.\(^{104–106}\) Azevedo et al.\(^{107}\) found that delivery mode might be associated with a higher carriage of oral fungi at a young age. Ward et al.\(^{108}\) highlighted that the mode of birth likely influence the fungal composition of the infant. It was believed that infants born vaginally appeared to have a higher level of *Candida* in their fecal mycobiome given that *Candida* was found predominantly in the vagina canal and they also had a more diverse mycobiome compared to those born by cesarean section (C-section) given the exposure of the infant to the mother’s fecal mycobiota. In contrast, infants delivered by C-section were colonized by a relatively higher abundance of *Malassezia* which originated from their mother’s skin. However, there are limited studies to support these hypotheses. In a separate study, Zhu et al.\(^{109}\) found that relative abundance of the order *Pleosporales* was higher in infants born via vaginal delivery than in those born by C-section.

*Mode of feeding.* Breast milk is considered the most ideal nutrition for infants offering protection from neonatal sepsis and facilitating infant growth and development.\(^{110}\) Several studies have...
shown that the mode of feeding impact on the gut bacterial microbiome. Boix-Amorós et al. characterized mycobiome composition in breast milk from healthy mothers and showed that the fungal composition of human breast milk was dominated by Malassezia (44%), followed by Candida (19%) and Saccharomyces (12%). The most abundant viable fungi detected were R. mucilaginosa and C. parapsilosis (Figure 2). Azevedo et al. suggested that the feeding mode of the infant (formula-fed or breast-fed infants) did not result in a difference in their oral yeast carriage. In contrast, Ward et al. suggested that feeding mode might affect the infant oral mycobiota. Currently, the relationship between infant and maternal gut mycobiome and whether breast milk leads to transmission of mycobiome from mother to infant remain controversial and require future studies. Future studies should focus on longitudinal tracking of the early-life mycobiota using mother–baby pairs while monitoring health outcomes during the first year of life. In addition, given the known interactions between the bacteria and fungi, future studies should also focus on the analysis of both bacteria and fungi to better characterize their structural and functional relationships, as well as their combined effects on health outcomes.

Gut mycobiota in elder subjects

Fungal community increased with age in infancy but decreased when they grow up to young adults (Figure 2). However, gut mycobiota alteration in elder subjects was less reported, and most of the older adults studied were reported with known diseases including hypertriglyceridemia (HG), Alzheimer’s disease (AD), and type 2 diabetes mellitus (T2DM). In Denmark, gut mycobiome analysis was performed in 100 elderly participants (70 with normotriglyceridemia versus 30 with hypertriglyceridemia) aged 65–81 years by ITS 2 amplicon sequencing on their fecal samples. Penicillium, Candida, and Aspergillus were the top three genera among the elderly Danes, and genus Penicillium was strongly correlated with the hypertriglyceridemia. Another study on 17 older subjects (11 mild cognitive impairment versus 6 cognitively normal) with average age of 64.6 years showed that Saccharomyces, Candida, and Aspergillus were major fungal genera in their fecal samples through ITS 1 sequencing. Higher abundance of Botrytis, Kazachstania, Phaeoacremonium, and Cladosporium and decreased abundance of Meyerozyma at genus level were found in the gut of patients with mild cognitive impairment compared with controls. Besides, Alonso et al. suggest that higher proportion of fungi were found in the brain tissue of older patients with AD compared with controls, and the percentages of Aspergillus and Candida were higher in elder controls than that in young controls by ITS 1 amplicon sequencing. However, to date no studies have fully profiled the longitudinal changes of mycobiota in the gut of old adults. Further studies are needed for a more complete picture of microbial development throughout the whole life.

The role of gut mycobiome and disease susceptibilities

Mycobiota and inflammatory bowel disease (IBD)

IBD, including ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic and relapsing, inflammatory disorder of the gastrointestinal tract. Its pathogenesis involves a complex interaction among host genetics, host immunity, microbiome, and environmental exposures. The alterations of fecal and mucosal mycobiota in IBD in the pediatric and adult populations were summarized in Figure 3. As early as 1990, anti-Saccharomyces cerevisiae antibodies (ASCA) were found to be significantly higher in sera of patients with CD, which suggests that the gut mycobiota may be involved in the pathogenesis of CD. Several studies have also confirmed increased ASCA titers in sera of CD patients and considered it as a potential biomarker for disease diagnosis. C. albicans was reported to be one of the immunogens for ASCA. Standaert-Vitse et al. showed that the pathogenic C. albicans in human tissues may induce overexpression of ASCA major epitopes. It was also shown that patients with CD and their first-degree healthy relatives were more frequently and more heavily colonized by C. albicans than healthy controls based on traditional culture method. Moreover, in vivo experiments suggested that colonic inflammation facilitated C. albicans colonization in dextran sodium sulfate-induced mice colitis model. Based on denaturing gradient gel electrophoresis (DGGE) analysis, Ott et al. showed that fungal diversity was increased in patients with CD compared with controls. Sokol et al. reported a distinct fungal microbiota dysbiosis in stool of
patients with IBD characterized by an increased Basidiomycota/Ascomycota ratio, decreased proportion of \textit{S. cerevisiae}, and an increased \textit{C. albicans} using ITS2 sequencing. Liguori \textit{et al.} profiled the fungal composition in colonic mucosa of patients with CD and healthy subjects and found an increase in fungus load during CD flare. In addition, \textit{Cystofilobasidiae} family, \textit{Diozegia} genera, and \textit{C. glabrata} species were overrepresented in CD while \textit{Leptosphaeria} and \textit{Trichosporon} genera were reduced compared with healthy controls. Similarly, a higher richness in fungal diversity in the inflamed mucosa of treatment-naive UC patients was detected when compared with noninflamed mucosa (Figure 3). However, after 5-ASA treatment, the richness of diversity declined.\textsuperscript{35} Furthermore, increased diversity of mucosal fungal microbiota was associated with expression of tumor necrosis factor (TNF)-\(\alpha\) and interferon (IFN)-\(\gamma\), which are key factors in the pathogenesis of IBD.\textsuperscript{4} In contrast to findings in adults, a reduced diversity in fungal microbiota was reported in the stool of pediatric patients with CD and UC.\textsuperscript{127} Besides, the represented fungal taxa detected in stool of pediatric patients with CD also differed from those of adults. Chehoud \textit{et al.}\textsuperscript{127} showed that \textit{C. utilis} and \textit{Candida parapsilosis} were more common in stool samples of children with IBD than healthy children via ITS1 Region Gene Sequencing. El Mouzan \textit{et al.}\textsuperscript{128} investigated fungal microbiota composition in treatment-naive children with CD and showed that \textit{Psathyrellaceae}, \textit{Cortinariaceae}, \textit{Psathyrella}, and \textit{Gymnopolis} were significantly increased in the mucosa, while \textit{Cortinariaceae}, \textit{Hymenochaetae}, and \textit{Gymnopilus} were enriched in stool samples. In addition, Lewis \textit{et al.} reported that \textit{S. cerevisiae}, \textit{Clavispora lusitaniae}, \textit{Candida utilis}, \textit{C. albicans}, and \textit{Kluyveromyces marxianus} were present in abundance in stools from 86 pediatric subjects with CD compared to controls using shotgun metagenomic analysis (Figure 3). Pediatric and adult subjects with CD shared a small proportion of fungal taxa but there is also distinct differences in the fungal species.\textsuperscript{129} These difference may be due to different clinical phenotypes, drugs, and gut bacterial community between adults and pediatric IBD subjects. Numerous studies have highlighted the interaction between fungi and bacteria in IBD. Several correlations between bacteria and fungi were observed in a pediatric cohort, which varied between the healthy controls and patients with CD.\textsuperscript{129} Hoarau reported a significant interkingdom associations in bacteriome and mycobiome in 13 familial clusters, which included 6 bacterial-fungal genus and 13 species-level correlations.\textsuperscript{69} In a DSS-induced mice colitis model, Sovran \textit{et al.}\textsuperscript{35} found that the beneficial effects of \textit{Saccharomyces boulardii} and pathogenic effects of \textit{C. albicans} on colitis severity could be eliminated through a broad-spectrum antibiotic cocktail treatment, including ampicillin, neomycin, metronidazole, and vancomycin. Overall, the gut fungal microbiota is altered in IBD but how fungi are involved in the occurrence and development of IBD remains unclear. Modulation of the fungal microbiota can be considered as a therapeutic approach for IBD as certain strains including \textit{S. boulardii} and \textit{S. cerevisiae} have shown therapeutic effects in human and murine IBD models. More studies on host–fungi interactions are necessary to enhance our understanding on how fungal microbiota interact with other constituents of the gut microbiota and the mechanisms of these relationships, in association with pathogenesis and development of IBD. Novel approaches, such as dietary interventions, probiotics, fecal microbiota transplantation (FMT), and antifungal metabolites to restore the dysbiotic states of intestinal mycobiota could be considered in the future; however, further studies are needed to assess their safety and efficacy.

**Gut mycobiome in colorectal cancer (CRC)**

Studies have shown that gut microbiota dysbiosis is associated with CRC.\textsuperscript{130} Besides bacteriome and virome, involvement of gut mycobiota in colorectal carcinogenesis has been increasingly recognized recently. Luan \textit{et al.} compared mucosa-adherent fungal microbiota of paired biopsy samples of adenomas with adjacent normal colon tissue and found that gut fungal diversity in adenomas was decreased compared with adjacent normal tissues. At the genus level, the opportunistic pathogens \textit{Phoma} and \textit{Candida} accounted for an average of 45% of the fungal microbiota. They also found an OTU, assigned to \textit{Spizellomyces}, to be significantly enriched in adenomas compared with adjacent samples while one OTU, assigned to \textit{Paraglomerales}, was significantly enriched in non-advanced adenomas compared with adjacent tissues. More importantly, \textit{Fusarium} and \textit{Trichoderma} genera, respectively, were significantly enriched in adjacent biopsy samples in advanced adenoma compared with samples of nonadvanced adenoma which may be useful for early diagnosis.\textsuperscript{6} In a mycobiome study of 29 polyps, 74 CRC patients, and
Figure 3. Schematic summary of the gut mycobiome alterations in IBD. Compared with healthy individuals, the gut mycobiome of patients with IBD is characterized by increased fungal diversity and mycobiota dysbiosis accompanying with inflammation. Increased Basidiomycota/Ascomycota ratio and Candida albicans level, decreased proportion of Saccharomyces cerevisiae were shown in the fecal samples of patients with IBD. Similarly, increased fungus load including of C. albicans, C. tropicalis, C. glabrata, and Gibberella moniliformis were also found in the intestinal mucosa of patients with IBD. Nevertheless, pediatric patients with IBD showed a decreased fungal diversity in the gut. C. albicans, C. utilis, C. parapsilosis, S. cerevisiae, Clavispora lusitaniae, and Kluyveromyces marxianus prevailed in the feces of children, while increased abundance of Psathyrellaceae, Cortinariaceae, Psathyrella, and Gymnopilus were detected in their mucosa.
28 healthy controls, fecal mycobiota composition differed among the three groups with a significant increase in the ratio of *Ascomycota* to *Basidiomycota* from control to CRC samples suggesting that changes of the gut mycobiota may be associated with progression of tumorigenesis. In addition, a higher fungal diversity was shown in late-stage CRC than in early-stage CRC. An increased proportion of opportunistic fungi *Trichosporon* and *Malassezia* was detected as the major contributor in the progression CRC. In a large multicenter study of 184 patients with CRC, 197 patients with adenoma and 204 control subjects, the ratio of *Basidiomycota*/*Ascomycota* was reported to be higher in CRC than in controls. In addition, six fungal features were detected to be enriched in CRC compared with controls at the genus level, including *Malassezia*, *Moniliophthora*, *Rhodotorula*, *Acremonium*, *Thielaviopsis*, and *Pisolithus*. A small cohort comparing mycobiota in patients with colitis-associated cancer (CAC) and sporadic cancer showed no difference in the fungal microbiota composition. Overall, fungal dysbiosis has been found in adenomas, CRC, or CAC. Understanding fungal diversity and abundance in CRC is crucial to help elucidate the potential contribution of fungal species in colorectal tumorigenesis and delineation of fecal fungal dysbiosis might shed light on new opportunities for utilizing fungal species as noninvasive diagnostic biomarkers for CRC or its precursor lesions.

**Gut mycobiome in metabolic diseases**

Animal and human studies support a role of gut fungi in metabolic disease. In a mouse model, Heisel et al. investigated the effects of obesogenic diet on fungal composition by ITS2 sequencing and found that *S. cerevisiae* in the gut was significantly more abundant in lean mice than in mice fed with a high-fat diet. In an obese subject (body weight index = 48.9), a higher fecal fungal diversity was observed compared with healthy lean individuals. Furthermore, by using parallel aerobic culture-dependent approach on 24 subjects and ITS-based sequencing on 52 subjects, impaired fungal communities were reported in the gut of obese individuals, characterized by an increased presence of the phylum *Ascomycota*, the class *Saccharomycetes*, and the families *Dipodascaceae* and *Saccharomytaceae* as compared with nonobese individuals. These findings suggest that obese subjects had altered gut fungi composition compared with their lean counterparts.

Mycobiome dysbiosis has also been reported in the gut of patients with diabetes mellitus. A higher diversity in fecal fungal species was found to distinguish children with type 1 diabetes mellitus (T1DM) from healthy controls. Moreover, a significantly increase in Candida colonization was found in the fecal samples of patients with type 1 and 2 diabetes compared with controls, which was verified by quantitative real-time PCR and medium cultures. In contrast, a separate study reported that *C. albicans* was significantly less prevalent in individuals with T1DM (62% of all strains identified) compared to control subjects (85% of all strains identified) based on medium cultures. Moreover, the fungal species isolated in this study were shown to be more resistant to anti-fungal drugs. Overall, the role of Candida in the pathogenesis of T1DM requires further confirmation. Using fungal ITS1 metagenomic sequencing on fecal samples from 10 healthy controls, 14 newly diagnosed T2DM, and 16 long-standing patients with T2DM, Bhute et al. found that opportunistic fungal pathogens such as *Aspergillus* and *Candida* were more abundant in newly diagnosed subjects compared with other groups. Jayasudha et al. used metagenomic sequencing to characterize fungal structure in fecal samples from 21 individuals with T2DM and 30 healthy controls. They found that patients with T2DM had increased fungal richness and evenness in the gut compared to healthy controls. An increase in the abundance of known human pathogens (genus *Candida*, *Kodamaea*, and *Meyerozyma*) and a decrease in the phylum *Mucoromycota* were noted in the gut of T2DM subjects.

Apart from altered gut mycobiome, altered fungal abundance in oral cavity was also reported in the subjects with diabetes mellitus. *C. albicans* and *C. glabrata* were both detected in the oral cavity of patients with T1DM. Nowakowska et al. suggested that *C. glabrata* resident in vagina and rectum was more than four times higher in women with diabetes than in nondiabetics. Significant associations were showed between glycemia and serum lipids with fungal abundance in patients with diabetes. Overall, these findings suggest that individuals with T2DM had gut mycobiome dysbiosis but whether this is the cause or consequence of the disease remains unknown. Most current studies are descriptive and longitudinal follow-up cohorts are important to delineate the importance of mycobiota dysbiosis in disease progression or complications in patients with diabetes mellitus.
Atherosclerosis is associated with metabolic diseases. Gut mycobiota dysbiosis has also been shown to be related with the development of carotid atherosclerosis. In a study of 33 subjects who had fecal samples collected for ITS amplicon sequencing, the subjects were divided into two groups of 12 nonobese subjects versus 21 obese subjects. The authors showed that the relative abundance of phylum Zygomycoza and family Mucoraceae and Mucor racemosus in the fecal samples of participants were negatively correlated with the carotid intima-media thickness and to the risk of subclinical atherosclerosis (using the Framingham risk scores) in prospective follow-up. A separate study compared gut mycobiome of 48 coronary atherosclerosis patients with healthy controls, and there was no significant difference in the fungal composition of fecal samples between both groups with ITS sequencing. However, the abundance of Thermosascus and species Malassezia restricta in the patients with coronary atherosclerosis was significantly lower than in healthy individuals, and the decrease of M. restricta might have a close association with lipid metabolism disorder in atherosclerosis patients. Altogether these findings implied the emerging role of the gut mycobiota on atherosclerosis. As cardiovascular and metabolic risks vary in individuals and can also be influenced by external factors including diet and lifestyle, multiomics studies incorporating metabolomics, transcriptomics, and the overall gut microbiome are needed.

Therapeutic approaches targeting the gut mycobiome

Pathogenic fungi infections have been a major challenge to global health and leads to significant morbidity and mortality. Recently, study suggested that host adaptive immune system could suppress harmful fungal effectors of pathogenic fungi in the gut to improve their commensal fitness, so as to maintain intestinal homeostasis in healthy state. However, pathogens such as C. albicans, C. neoformans, and Aspergillus fumigatus could present a threat to immunocompromised individuals. In subjects with fungal infections, antifungal drugs are generally used as the first choice to clear the pathogens. Current antifungal drugs in clinical use consist of azoles (disruption of fungal ergosterol synthesis), polyenes (breakdown of membranes), echinocandins (inhibition of cell wall synthesis), and pyrimidines (inhibition of DNA synthesis and miscoding of RNA). Invasive candidiasis is a frequent health-care-associated fungal infection caused by C. albicans, C. glabrata, and C. tropicalis. Mortality of this fungi infection is up to 40% annually. Amphotericin B deoxycholate and micafungin treatments are effective to control the infections. Recently alterations in the gut mycobiome have been reported in fecal samples of patients admitted to hospital with coronavirus disease (COVID-19) with increased proportions of opportunistic fungal pathogens, C. albicans, C. auris, and A. flavus compared with controls. Importantly, two respiratory-associated fungal pathogens, A. flavus and Aspergillus niger, were detected in fecal samples from a subset of patients with COVID-19, even after clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from nasopharyngeal samples and resolution of respiratory symptoms. In sick individuals, Aspergillus sp. (A. fumigatus, A. penicillioides, A. niger and A. flavus) were detected in the endotracheal aspirate or bronchoalveolar lavage fluid imposing a high risk developing complicating invasive pulmonary aspergillosis. Antifungal therapies, such as voriconazole and isavuconazole, were commonly used for preventing pulmonary aspergillosis and reducing mortality. However, toxicities and drug–drug interactions limit the utility of current antifungal drugs. Ubiquity use of antifungal drugs has contributed to our reliance on fungicides and the emergence of multidrug-resistant pathogenic fungi.

Diet could be one of the major driving force influencing gut fungal mycobiota structure. A high-fat diet changed the gut fungal communities in murine models. It was reported that the abundances of the Alternaria, Saccharomyces, Septoriella, and Tilletiopsis genera were higher in mice administrated with normal chow compared with those fed with high-fat diet. Moreover, diet rich in plant-derived carbohydrate can support Candida in the gut of Indian subjects, while saturated fatty acid and coconut oil–rich diet negatively correlated with the load of Candida in the gut. In addition, dietary short-chain fatty acids correlated with decreased colonization of Aspergillus spp.

Probiotics and prebiotics have been designed to provide health benefit. Multiple studies have identified several bacteria species with antifungal effects in vitro experiments, like Lactobacillus spp. and Bifidobacterium spp. In mice models, oral heat-killed Lactobacillus acidophilus (HKLA)
and heat killed *Lactobacillus casei* could decrease the colonization of viable *C. albicans* in the tract. Colitis would induce overgrowth of opportunistic yeast pathogen *C. glabrata* in murine gut. Mice with colitis treated with β-glucans presented a decreased level of *C. glabrata* in the gut compared the colitis mice. Mycobiota regulation with probiotics and prebiotics in human study is rare, increasing evidences provide the possibility that the antagonistic relationships between bacterial and fungal species may decrease the perturbations and enhance the cross-talks in the gut to establish a balanced microbial community.

Other than bacteria, fungal probiotics could also confer beneficial effects to support human health. *S. cerevisiae* and *S. boulardii* are the most common yeast. *S. boulardii* has shown the potential abilities to alleviate gastrointestinal disorder caused by *Helicobacter pylori*, *Salmonella*, and *Clostridium difficile*. In the gut of patients with IBD, the environment may favor fungi over bacteria, leading to both fungal and bacterial microbiome dysbiosis. Guslandi has demonstrated that *S. boulardii* could be used to treat IBD effectively, modulating the microbial composition in the gut. However, whether *S. boulardii* was involved in the restoration of mycobiome composition in the gut remains unknown. Understanding how probiotics interplay with fungal community to maintain or restore a stable ecosystem and improve human health remains a challenge for future work.

Fecal microbiome transplantation (FMT) is the transfer of stool from a healthy individual to the gastrointestinal tract of another individual to re-establish the balance of microbiome. Up to date, the effective application of FMT in treating patients with recurrent *Clostridium difficile*-associated diarrhea (CDI), IBD, and irritable bowel syndrome (IBS) have been successively demonstrated. The efficacy of FMT is also associated with mycobiota. CDI is accompanied by outgrowth of *C. albicans* and dysbiosis in fungal diversity. High levels of *Saccharomyces* and *Aspergillus* in donor stool were reported in FMT responders, while nonresponders were related to a high abundance of *C. albicans*. The results implied that FMT is a promising therapy to improve gut mycobiome dysbiosis in CDI patients, while the fungi also have a tight association with FMT treatment outcomes.

**Future perspective**

Here we review the existing literature on the human gut mycobiome in order to provide a comprehensive insight into both the methodologies available to research the gut mycobiota and also to highlight the latest research findings. We also draw on research into what is known about the human mycobiome composition at diseases and early life in order to provide both comparative insight and productive direction for future studies in this burgeoning research area. Studies performed so far have shown potential links of mycobiome in health and diseases, it is important to demonstrate the causation rather than association. An increasing body of evidence suggests the alteration of interkingdom microbial community alterations contributing to the detrimental consequences to the host. To expand our knowledge and obtain deeper insight into the role of the microbiome in health and disease, future studies should characterize the different microorganisms (bacteria, fungi, and viruses) in the same sample types and inter-kingdom microbial community. Future challenge will be to understand these interactions on both the molecular level and in their complexity. To meet this challenge, improved approaches and collaborations among bacteriologists, mycologists, immunologists, and clinicians are required to develop the foundation for personalized microbiome medicine. A better understanding of the fungi–bacteria–host interactions can allow identification of patients who are at risk and improvement of patient care by tailored manipulation of the microbiota.

**Author contributions**

Lin Zhang and Hui Zhan were joint first authors.

**Conflict of interest statement**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Siew C. Ng https://orcid.org/0000-0002-6850-4454
References
1. Iliev ID and Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nat Rev Immunol 2017; 17: 635–646.
2. Soverini M, Turroni S, Biagi E, et al. HumanMycobiomeScan: a new bioinformatics tool for the characterization of the fungal fraction in metagenomic samples. BMC Genomics 2019; 20: 496.
3. Liguori G, Lamas B, Richard ML, et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients. J Crohns Colitis 2016; 10: 296–305.
4. Li Q, Wang C, Tang C, et al. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn’s disease. J Clin Gastroenterol 2014; 48: 513–523.
5. Zhang F, Zuo T, Yeo YK, et al. Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease. Nat Commun 2021; 12: 65.
6. Luan C, Xie L, Yang X, et al. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. Sci Rep 2015; 5: 7980.
7. Gao R, Kong C, Li H, et al. Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. Eur J Clin Microbiol Infect Dis 2017; 36: 2457–2468.
8. Coker OO, Nakatsu G, Dai RZ, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut 2019; 68: 654–662.
9. Botschuijver S, Roeselers G, Levin E, et al. Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats. Gastroenterology 2017; 153: 1026–1039.
10. Li M, Dai B, Tang Y, et al. Altered bacterial-fungal interkingdom networks in the guts of ankylosing spondylitis patients. Mystems 2019; 4: e00176-18.
11. Jiang HY, Pan LY, Zhang X, et al. Altered gut bacterial–fungal interkingdom networks in patients with current depressive episode. Brain Behav 2020; 10: e01677.
12. Zhang X, Pan L-y, Zhang Z, et al. Analysis of gut mycobiota in first-episode, drug-naive Chinese patients with schizophrenia: a pilot study. Behav Brain Res 2020; 379: 112374.
13. Li X, Leonardi I, Semon A, et al. Response to fungal dysbiosis by gut-resident CX3CR1+ mononuclear phagocytes aggravates allergic airway disease. Cell Host Microbe 2018; 24: 847–856.e844.
14. Leonardi I, Li X, Semon A, et al. CX3CR1+ mononuclear phagocytes control immunity to intestinal fungi. Science 2018; 359: 232–236.
15. Limon JJ, Tang J, Li D, et al. Malassezia is associated with Crohn’s disease and exacerbates colitis in mouse models. Cell Host Microbe 2019; 25: 377–388.e376.
16. Iliev ID, Funari VA, Taylor KD, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 2012; 336: 1314–1317.
17. Rodríguez MM, Pérez D, Chaves FJ, et al. Obesity changes the human gut mycobiome. Sci Rep 2015; 5: 14600.
18. Steinert RE, Rehman A, Souto Lima EJ, et al. Roux-en-Y gastric bypass surgery changes fungal and bacterial microbiota in morbidly obese patients – a pilot study. PLoS One 2020; 15: e0236936.
19. Jayasudha R, Das T, Kalyana Chakravarthy S, et al. Gut mycobiomes are altered in people with type 2 diabetes mellitus and diabetic retinopathy. PLoS One 2020; 15: e0243077.
20. Al Bataineh MT, Dash NR, Lassen PB, et al. Revealing links between gut microbiome and its fungal community in type 2 diabetes mellitus among Emirati subjects: a pilot study. Sci Rep 2020; 10: 9624.
21. van der Merwe M, Sharma S, Caldwell JL, et al. Time of feeding alters obesity-associated parameters and gut bacterial communities, but not fungal populations, in C57bl/6 male mice. Curr Dev Nutr 2020; 4: nzz145.
22. Arrieta M-C, Arévalo A, Stiemsma L, et al. Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting. J Allergy Clin Immunol 2018; 142: 424–434.e410.
23. Honkanen J, Vuorela A, Muthas D, et al. Fungal dysbiosis and intestinal inflammation in children with beta-cell autoimmunity. Front Immunol 2020; 11: 468.
24. Boix-Amorós A, Puente-Sánchez F, Du Toit E, et al. Mycobiome profiles in breast milk from healthy women depend on mode of delivery, geographic location, and interaction with bacteria. Appl Environ Microbiol 2019; 85: e02994-18.
25. Heisel T, Nyaribo L, Sadowsky MJ, et al. Breastmilk and NICU surfaces are potential sources of fungi for infant mycobiomes. Fungal Genet Biol 2019; 128: 29–35.
26. Willis KA, Purvis JH, Myers ED, et al. Fungi form interkingdom microbial communities in the primordial human gut that develop with gestational age. *FASEB J* 2019; 33: 12825–12837.

27. James SA, Phillips S, Telatin A, et al. Preterm infants harbour a rapidly changing mycobiota that includes Candida pathobionts. *J Fungi* 2020; 6: 273.

28. Doron I, Leonard I and Iliev ID. Profound mycobiome differences between segregated mouse colonies do not influence Th17 responses to a newly introduced gut fungal commensal. *Fungal Genet Biol* 2019; 127: 45–49.

29. Mueller KD, Zhang H, Serrano CR, et al. Gastrointestinal microbiota alteration induced by Murcor cirrhineioides in a murine model. *J Microbiol* 2019; 57: 509–520.

30. Panpetch W, Somboonna N, Palasuk M, et al. Oral Candida administration in a Clostridium difficile mouse model worsens disease severity but is attenuated by Bifidobacterium. *PLoS ONE* 2019; 14: e0210798.

31. Skalski JH, Limon JJ, Sharma P, et al. Expansion of commensal fungus Wallemia mellicola in the gastrointestinal mycobiota enhances the severity of allergic airway disease in mice. *PLoS Pathog* 2018; 14: e1007260.

32. Arunasri K, Mahesh M, Sai Prashanthi G, et al. Mycobiome changes in the vitreous of post fever retinitis patients. *PLoS Pathog* 2020; 16: e1002138.

33. Jun X, Ning C, Yang S, et al. Alteration of fungal microbiota after 5-ASA treatment in UC patients. *Inflamm Bowel Dis* 2020; 26: 380–390.

34. Di Paola M, Rizzetto L, Stefaniini I, et al. Comparative immunophenotyping of Saccharomyces cerevisiae and Candida spp. strains from Crohn’s disease patients and their interactions with the gut microbiome. *J Transl Autoimmun* 2020; 3: 100036.

35. Sovran B, Planchais J, Jegou S, et al. Enterobacteriaceae are essential for the modulation of colitis severity by fungi. *Microbiome* 2018; 6: 152.

36. Hong G, Li Y, Yang M, et al. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: an explorative study. *Neurogastroenterol Motil* 2020; 32: e13891.

37. Stewart DB, Wright JR, Fowler M, et al. Integrated meta-omics reveals a fungus-associated bacteriome and distinct functional pathways in Clostridioides difficile infection. *mSphere* 2019; 4: e00454-19.

38. Mukherjee PK, Sendid B, Hoarau G, et al. Mycobiota in gastrointestinal diseases. *Nat Rev Gastroenterol Hepatol* 2015; 12: 77–87.

39. Fiedorová K, Radvanský M, Bosák J, et al. Bacterial but not fungal gut microbiota alterations are associated with common variable immunodeficiency (CVID) phenotype. *Front Immunol* 2019; 10: 1914.

40. Annavajhala MK, Khan SD, Sullivan SB, et al. Oral and gut microbial diversity and immune regulation in patients with HIV on antiretroviral therapy. *mSphere* 2020; 5: e00798-19.

41. Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. *J Hepatol* 2020; 72: 391–400.

42. Marcelino VR, Holmes EC and Sorrell TC. The use of taxon-specific reference databases compromises metagenomic classification. *BMC Genomics* 2020; 21: 184.

43. Suhr MJ, Banjara N and Hallen-Adams HE. Sequence-based methods for detecting and evaluating the human gut mycobiome. *Let Appl Microbiol* 2016; 62: 209–215.

44. Gouba N, Raoul D and Drancourt M. Eukaryote culturomics of the gut reveals new species. *PLoS One* 2014; 9: e106994.

45. Frau A, Kenny JG, Lenzi L, et al. DNA extraction and amplicon production strategies deeply influence the outcome of gut mycobiome studies. *Sci Rep* 2019; 9: 9328.

46. Hamad I, Ranque S, Azhar EI, et al. Culturomics and amplicon-based metagenomic approaches for the study of fungal population in human gut microbiota. *Sci Rep* 2017; 7: 16788.

47. Fiedorová K, Radvanský M, Němcová E, et al. The impact of DNA extraction methods on stool bacterial and fungal microbiota community recovery. *Front Microbiol* 2019; 10: 821.

48. Arafken AM, Frey JF, Ramsay TG, et al. Yeasts of the piglet GI tract. *Front Microbiol* 2019; 10: 2286.

49. Huseyin CE, Rubio RC, O’Sullivan O, et al. The fungal frontier: a comparative analysis of methods used in the study of the human gut mycobiome. *Front Microbiol* 2017; 8: 1432.

50. Akyt B, Pushalkar S, Chen R, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. *Nature* 2019; 574: 264–267.

51. Nagpal R, Neth BJ, Wang S, et al. Gut mycobiome and its interaction with diet, gut bacteria and Alzheimer’s disease markers in...
subjects with mild cognitive impairment: a pilot study. *EBioMedicine* 2020; 59: 102950.

52. Seelbinder B, Chen J, Brunke S, et al. Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria. *Microbiome* 2020; 8: 133.

53. Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. *Nat Microbiol* 2016; 1: 16113.

54. El Jurdi N, Filali-Mouhim A, Salem I, et al. Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. *PLoS Pathog* 2014; 10: e1003996.

55. Hagan T, Cortese M, Rouphael N, et al. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. *Cell* 2019; 178: 1313–1328.e1313.

56. Rush TA, Puech-Pagès V, Bascaules A, et al. Lipo-chitooligosaccharides as regulatory signals of fungal growth and development. *Nat Commun* 2020; 11: 3897.

57. Calusinska M, Marynowska M, Bertucci M, et al. Integrative omics analysis of the termite gut system adaptation to Miscanthus diet identifies lignocellulose degradation enzymes. *Commun Biol* 2020; 3: 275.

58. Motooka D, Fujimoto K, Tanaka R, et al. Fungal ITS1 deep-sequencing strategies to reconstruct the composition of a 26-species community and evaluation of the gut mycobiota of healthy Japanese individuals. *Front Microbiol* 2017; 8: 238.

59. Bajaj JS, Liu EJ, Kheradman R, et al. Fungal dysbiosis in cirrhosis. *Gut* 2018; 67: 1146–1154.

60. Wu L, Zeng T, Deligios M, et al. Age-related variation of bacterial and fungal communities in different body habitats across the young, elderly, and centenarians in Sardinia. *msphere* 2020; 5: e00558-19.

61. Mahnic A and Rupnik M. Different host factors are associated with patterns in bacterial and fungal gut microbiota in Slovenian healthy cohort. *PLoS One* 2018; 13: e0209209.

62. Hagen LH, Brooke CG, Shaw CA, et al. Proteomic specialization of anaerobic fungi during ruminal degradation of recalcitrant plant fiber. *ISME J* 2021; 15: 421–434.

63. Zuo T, Zhan H, Zhang F, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge. *Gastroenterology* 2020; 159: 1302–1310.e1305.

64. Arfken AM, Frey JF and Summers KL. Temporal dynamics of the gut bacteriome and mycobiome in the weanling pig. *Microorganisms* 2020; 8: 868.

65. Ghannoum MA, Jurevic RJ, Mukherjee PK, et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog* 2010; 6: e1000713.

66. Mukherjee PK, Chandra J, Retuerto M, et al. Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. *PLoS Pathog* 2014; 10: e1003996.

67. Chen Y, Chen Z, Guo R, et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. *Diagn Microbiol Infect Dis* 2011; 70: 492–498.

68. Schoch CL, Seifert KA, Huhndorf S, et al. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi. *Proc Natl Acad Sci USA* 2012; 109: 6241–6246.

69. Hoarau G, Mukherjee P, Gower-Rousseau C, et al. Bacteriome and mycobiome interactions underscore microbial dysbiosis in familial Crohn’s disease. *mBio* 2016; 7: e01250-16.

70. Valinsky L, Della Vedova G, Jiang T, et al. Oligonucleotide fingerprinting of rRNA genes for analysis of fungal community composition. *Appl Environ Microbiol* 2002; 68: 5999–6004.

71. Auchtung TA, Fofanova TY, Stewart CJ, et al. Investigating colonization of the healthy adult gastrointestinal tract by fungi. *msphere* 2018; 3: e00092-18.

72. Fiers WD, Gao IH and Iliev ID. Gut mycobiota under scrutiny: fungal symbionts or environmental transients? *Curr Opin Microbiol* 2019; 50: 79–86.

73. Moreno-Sabater A, Autaa G, Sterlin D, et al. Systemic anti-commensal response to fungi analyzed by flow cytometry is related to gut mycobiome ecology. *Microbiome* 2020; 8: 159.

74. Harris VC, Haak BW, Handley SA, et al. Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-concept trial. *Cell Host Microbe* 2018; 24: 197–207.e194.

75. Rosshart SP, Herz J, Vassallo BG, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. *Science* 2019; 365: eaaw4361.
76. Morrison GA, Fu J, Lee GC, et al. Nanopore sequencing of the fungal intergenic spacer sequence as a potential rapid diagnostic assay. J Clin Microbiol 2020; 58: e01972-20.

77. Loit K, Adamson K, Bahram M, et al. Relative performance of MinION (Oxford Nanopore Technologies) versus Sequel (Pacific Biosciences) third-generation sequencing instruments in identification of agricultural and forest fungal pathogens. Appl Environ Microbiol 2019; 85: e01368-19.

78. Leidenfrost RM, Pöther D-C, Jäckel U, et al. Benchmarking the MinION: evaluating long reads for microbial profiling. Sci Rep 2020; 10: 5125.

79. Nilsson RH, Anslan S, Bahram M, et al. Mycobiome diversity: high-throughput sequencing and identification of fungi. Nat Rev Microbiol 2019; 17: 95–109.

80. D’Andreano S, Cuscó A and Francino O. Rapid and real-time identification of fungi up to species level with long amplicon nanopore sequencing from clinical samples. Biol Methods Protoc 2020; 6: bpa026.

81. Cui L, Morris A and Ghedin E. The human mycobiome in health and disease. Genome Med 2013; 5: 63.

82. Li S, Deng Y, Wang Z, et al. Exploring the accuracy of amplicon-based internal transcribed spacer markers for a fungal community. Mol Ecol Resour 2020; 20: 170–184.

83. Bellemain E, Carlsen T, Brochmann C, et al. ITS as an environmental DNA barcode for fungi: an in silico approach reveals potential PCR biases. BMC Microbiol 2010; 10: 189.

84. Smirnov E, Chmůrějíková N, Liška F, et al. Variability of human rDNA. Cells 2021; 10: 196.

85. Wagner K, Springer B, Pires V, et al. Molecular detection of fungal pathogens in clinical specimens by 18S rDNA high-throughput screening in comparison to ITS PCR and culture. Sci Rep 2018; 8: 6964.

86. Gao B, Chi L, Zhu Y, et al. An introduction to next generation sequencing bioinformatic analysis in gut microbiome studies. Biomolecules 2021; 11: 530.

87. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome 2017; 5: 153.

88. Strati F, Di Paola M, Stefanini I, et al. Age and gender affect the composition of fungal population of the human gastrointestinal tract. Front Microbiol 2016; 7: 1227.

89. Perfect J and Casadrevall A. Molecular principles of fungal pathogenesis. Washington, DC: ASM Press, 2006.

90. Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 2013; 8: e66019.

91. Hallen-Adams HE, Kachman SD, Kim J, et al. Fungi inhabiting the healthy human gastrointestinal tract: a diverse and dynamic community. Fungal Ecol 2015; 15: 9–17.

92. Raimondi S, Amaretti A, Gozzoli C, et al. Longitudinal survey of fungi in the human gut: its profiling, phenotyping, and colonization. Front Microbiol 2019; 10: 1575.

93. Khatib R, Riederer KM, Ramanathan J, et al. Faecal fungal flora in healthy volunteers and inpatients. Mycoses 2001; 44: 151–156.

94. Sonnenburg JL, Angenent LT and Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569–573.

95. Sam QH, Chang MW and Chai LYA. The fungal mycobiome and its interaction with gut bacteria in the host. Int J Mol Sci 2017; 18: 330.

96. Ott SJ, Kühbacher T, Musfeldt M, et al. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol 2008; 43: 831–841.

97. Merchant HA, McConnell EL, Liu F, et al. Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. Eur J Pharm Sci 2011; 42: 3–10.

98. Zhong M, Xiong Y, Zhao J, et al. Candida albicans disorder is associated with gastric carcinogenesis. Theranostics 2021; 11: 4945.

99. Wampuch L, Heintz-Buschart A, Hogan A, et al. Colonization and succession within the human gut microbiome by archaea, bacteria, and microeukaryotes during the first year of life. Front Microbiol 2017; 8: 738.

100. Schei K, Avershina E, Øien T, et al. Early gut mycobiota and mother-offspring transfer. Microbiome 2017; 5: 107.

101. Ward TL, Dominguez-Bello MG, Heisel T, et al. Development of the human mycobiome over the first month of life and across body sites. mSystems 2018; 3: e00140-17.

102. Yassour M, Jason E, Hogstrom LJ, et al. Strain-level analysis of mother-to-child bacterial diversity: high-throughput sequencing and identification of fungi. Mol Ecol Resour 2020; 20: 196.
transmission during the first few months of life. Cell Host Microbe 2018; 24: 146–154.e144.

103. Ferretti P, Pasolli E, Tett A, et al. Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome. Cell Host Microbe 2018; 24: 133–145.e135.

104. Mueller NT, Bakacs E, Combellick J, et al. The infant microbiome development: mom matters. Trends Mol Med 2015; 21: 109–117.

105. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010; 107: 11971–11975.

106. Grice EA and Segre JA. The skin microbiome. Nat Rev Microbiol 2011; 9: 244–253.

107. Azevedo MJ, de Lurdes Pereira M, Araujo R, et al. Influence of delivery and feeding mode in oral fungi colonization – a systematic review. Microb Cell 2020; 7: 36–45.

108. Ward TL, Knights D and Gale CA. Infant fungal communities: current knowledge and research opportunities. BMC Med 2017; 15: 30.

109. Zhu T, Duan Y-Y, Kong F-Q, et al. Dynamics of skin mycobiome in infants. Front Microbiol 2020; 11: 1790.

110. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr 2010; 156(Suppl. 2): S3–S7.

111. Bokulich NA, Chung J, Battaglia T, et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci Transl Med 2016; 8: 343ra82.

112. Shaö Y, Forster SC, Tsaliíki E, et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 2019; 574: 117–121.

113. Boix-Amorós A, Martinez-Costa C, Querol A, et al. Multiple approaches detect the presence of fungi in human breastmilk samples from healthy mothers. Sci Rep 2017; 7: 13016.

114. Barrera-Vázquez OS and Gomez-Verjan JC. The unexplored world of human virome, mycobiome, and archaeome in aging. J Gerontol A Biol Sci Med Sci 2020; 75: 1834–1837.

115. Ahmad HF, Mejia JLC, Krych L, et al. Gut mycobiome dysbiosis is linked to hypertriglycerideremia among home dwelling elderly Danes. bioRxiv. Epub ahead of print 17 April 2020. DOI: 10.1101/2020.04.16.044693.

116. Alonso R, Pisa D, Fernández-Fernández AM, et al. Infection of fungi and bacteria in brain tissue from elderly persons and patients with Alzheimer’s disease. Front Aging Neurosci 2018; 10: 159.

117. Ye Y, Pang Z, Chen W, et al. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med 2015; 8: 22529–22542.

118. McKenzie H, Main J, Pennington C, et al. Antibody to selected strains of Saccharomyces cerevisiae (baker’s and brewer’s yeast) and Candida albicans in Crohn’s disease. Gut 1990; 31: 536–538.

119. Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn’s disease and ulcerative colitis: a GISc study. Am J Gastroenterol 2001; 96: 2407–2412.

120. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822–829.

121. Sendid B, Quinton J-F, Charrier G, et al. Anti-Saccharomyces cerevisiae cerevisiae mannan antibodies in familial Crohn’s disease. Am J Gastroenterol 1998; 93: 1306–1310.

122. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae cerevisiae antibody markers of Crohn’s disease. Gut Microbiol 2006; 130: 1764–1775.

123. Standaert-Vitse A, Sendid B, Joossens M, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol 2009; 104: 1745–1753.

124. Panpetch W, Hiengrach P, Nilgate S, et al. Additional Candida albicans administration enhances the severity of dextran sulfate sodium-induced colitis mouse model through leaky gut-enhanced systemic inflammation and gut-dysbiosis but attenuated by Lactobacillus rhamnosus L34. Gut Microbes 2020; 11: 465–480.

125. Jawhara S, Thuru X, Standaert-Vitse A, et al. Antibody to selected strains of Saccharomyces cerevisiae mannan antibodies in Crohn’s disease of familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn’s disease. Am J Gastroenterol 2001; 96: 2407–2412.

126. Sokol H, Leducq V, Aschard H, et al. Fungal signature in the gut microbiota of familial Crohn’s disease. Cell Host Microbe 2008; 197: 972–980.

127. Chehoud C, Albenberg LG, Judge C, et al. Stunted gut microbiota dysbiosis but attenuated by Lactobacillus gasseri L34. Gut Microbes 2020; 11: 465–480.
pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2015; 21: 1948–1956.

128. El Mouzan M, Wang F, Al Mofarreh M, et al. Fungal microbiota profile in newly diagnosed treatment-naive children with Crohn’s disease. *J Crohns Colitis* 2017; 11: 586–592.

129. Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. *Cell Host Microbe* 2015; 18: 489–500.

130. Louis P, Hold GL and Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. *Nat Rev Microbiol* 2014; 12: 661–672.

131. Richard ML, Liguori G, Lamas B, et al. Mucosa-associated microbiota dysbiosis in colitis associated cancer. *Gut Microbes* 2018; 9: 131–142.

132. Chacon M, Lozano-Bartolome J, Portero-Otin M, et al. The gut mycobiome composition is linked to carotid atherosclerosis. *Benef Microbes* 2018; 9: 185–198.

133. Heisel T, Montassier E, Johnson A, et al. High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut. *mSphere* 2017; 2: e00351-17.

134. Gouba N, Raoult D and Drancourt M. Plant and fungal diversity in gut microbiota as revealed by molecular and culture investigations. *PLoS ONE* 2013; 8: e59474.

135. Borges FM, de Paula TO, Sarmiento MRA, et al. Fungal diversity of human gut microbiota among eutrophic, overweight, and obese individuals based on aerobic culture-dependent approach. *Carr Microbiol* 2018; 75: 726–735.

136. Kowalewska B, Zorena K, Szmigiero-Kawko M, et al. Higher diversity in fungal species discriminates children with type 1 diabetes mellitus from healthy control. *Patient Prefer Adherence* 2016; 10: 591–599.

137. Gosiewski T, Salamon D, Szopa M, et al. Quantitative evaluation of fungi of the genus Candida in the feces of adult patients with type 1 and 2 diabetes-a pilot study. *Gut Pathog* 2014; 6: 43–45.

138. Soyucen E, Gulcan A, Aktuglu-Zeybek AC, et al. Differences in the gut microbiota of healthy children and those with type 1 diabetes. *Pediatr Int* 2014; 56: 336–343.

139. Bhute SS, Suryavanshi MV, Joshi SM, et al. Gut microbial diversity assessment of Indian type-2-diabetics reveals alterations in eubacteria, archaea, and eukaryotes. *Front Microbiol* 2017; 8: 214.

140. Aly F, Blackwell C, MacKenzie D, et al. Chronic atrophic oral candidiasis among patients with diabetes mellitus–role of secretor status. *Epidemiol Infect* 1991; 106: 355–363.

141. Nowakowska D, Kurnatowska A, Stray-Pedersen B, et al. Species distribution and influence of glycemic control on fungal infections in pregnant women with diabetes. *J Infect* 2004; 48: 339–346.

142. Marin de Evsikova C, Raplee ID, Lockhart J, et al. The transcriptomic toolbox: resources for interpreting large gene expression data within a precision medicine context for metabolic disease atherosclerosis. *J Pers Med* 2019; 9: 21.

143. Xu J, Zhang Y, Wang X, et al. Changes and roles of intestinal fungal microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. *Am J Transl Res* 2020; 12: 3445–3460.

144. Ost KS, O’Meara TR, Stephens WZ, et al. Adaptive immunity induces mutualism between commensal eukaryotes. *Nature* 2021; 596: 114–118.

145. Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. *Sci Transl Med* 2012; 4: 165rv113.

146. Robbins N, Wright GD and Cowen LE. Antifungal drugs: the current armamentarium and development of new agents. In: Heitman J, Stukenbrock EH, Gow NAR (eds) *The fungal kingdom*. New York: Wiley, 2017, pp. 903–922.

147. Kullberg BJ and Arendrup MC. Invasive candidiasis. *N Engl J Med* 2015; 373: 1445–1456.

148. Peçanha-Pietrobom PM and Colombo AL. Mind the gaps: challenges in the clinical management of invasive candidiasis in critically ill patients. *Curr Opin Infect Dis* 2020; 33: 441–448.

149. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009; 48: 503–535.

150. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis* 2007; 45: 883–893.
151. Prattles J, Valentín T, Hoenigl M, et al. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU—a case report. *Med Mycol Case Rep* 2021; 31: 2–5.

152. Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. *Clin Infect Dis*. Epub ahead of print 28 July 2020. DOI: 10.1093/cid/ciaa1065.

153. Sharma A, Hofmeyr A, Bansal A, et al. COVID-19 associated pulmonary aspergillosis (CAPA): an Australian case report. *Med Mycol Case Rep* 2021; 31: 6–10.

154. Fisher MC, Hawkins NJ, Sanglard D, et al. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. *Science* 2018; 360: 739–742.

155. Vargas SL, Patrick C, Ayers G, et al. Modulating effects of dietary carbohydrate supplementation on Candida albicans colonization and invasion in a neutropenic mouse model. *Infect Immun* 1993; 61: 619–626.

156. Gunsalus KT, Tornberg-Belanger SN, Matthan NR, et al. Manipulation of host diet to reduce gastrointestinal colonization by the opportunistic pathogen Candida albicans. *mSphere* 2016; 1: e00020-15.

157. Pareek S, Kurakawa T, Das B, et al. Comparison of Japanese and Indian intestinal microbiota shows diet-dependent interaction between bacteria and fungi. *NPJ Biofilms Microbiomes* 2019; 5: 37–13.

158. Payne S, Gibson G, Wynne A, et al. In vitro studies on colonization resistance of the human gut microbiota to Candida albicans and the effects of tetracycline and Lactobacillus plantarum LPK. *Curr Issues Intest Microbiol* 2003; 4: 1–8.

159. de Barros PP, Scorzoni L, Ribeiro FC, et al. Lactobacillus paracasei 28.4 reduces in vitro mycelial formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans. *Microb Pathog* 2018; 117: 80–87.

160. Ghavzini RD, Kouhsari E, Zibafar E, et al. Antifungal activity and aflatoxin degradation of Bifidobacterium bifidum and Lactobacillus fermentum against toxigenic Aspergillus parasiticus. *Open Microbiol J* 2016; 10: 197–201.

161. Wagner R, Pierson C, Warner T, et al. Probiotic effects of feeding heat-killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans–colonized immunodeficient mice. *J Food Prot* 2000; 63: 638–644.

162. Charlet R, Bortolus C, Barbet M, et al. A decrease in anaerobic bacteria promotes Candida glabrata overgrowth while β-glucan treatment restores the gut microbiota and attenuates colitis. *Gut Pathogens* 2018; 10: 50.

163. García-Bayona L and Comstock LE. Bacterial antagonism in host-associated microbial communities. *Science* 2018; 361: eaat2456.

164. Cortheir G, Dubos F and Ducluzeau R. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. *Can J Microbiol* 1986; 32: 894–896.

165. Duman DG, Bor S, Ozütemiz O, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. *Eur J Gastroenterol Hepatol* 2005; 17: 1357–1361.

166. Martins FS, Vieira AT, Elian SD, et al. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. *Microbes Infect* 2013; 15: 270–279.

167. Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? *Nat Rev Microbes* 2017; 14: 573–584.

168. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. *Dig Dis Sci* 2000; 45: 1462–1464.

169. Guslandi M, Giollo P and Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. *Eur J Gastroenterol Hepatol* 2003; 15: 697–698.

170. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? *Am J Gastroenterol* 2012; 107; 1755; author reply p. 1755–1756.

171. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. *Clin Gastroenterol Hepatol* 2011; 9: 1044–1049.

172. Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. *JAMA* 2019; 321: 156–164.

173. Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. *Am J Gastroenterol* 2019; 114: 1043–1050.